However, this mutation is not actionable in clinical practice, unlike the less common mutations of MDM2 and CDK4 found in our cases, whose value as predictive markers for response to specific drugs is being evaluated in a series of clinical trials that could change the therapeutic landscape in the treatment of sarcomas, which up to now has been dominated by a one-size-fits-all chemotherapy approach (22, 23). The gene discussed is CDK4; the disease is sarcoma.